Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AnHeart Therapeutics
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart